I - Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
Tachycardia
Last update 17/06/2026
Search for exposure to B2 agonists, theophylline, epinephrine, thyroid hormones, and abused substances/drugs recommended
I - Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
Last update 17/06/2026
Search for exposure to B2 agonists, theophylline, epinephrine, thyroid hormones, and abused substances/drugs recommended
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.f Tachycardia
III. Myocardial ischemia - Coronary artery disease
III.a Coronary artery disease (acute) - Myocardial ischemia/infarction
XXVIII. Large airway involvement
XXVIII.a Angioedema (may cause UAO, asphyxia and death)
XXXVI. Autoimmune syndromes - Systemic reactions or conditions
XXXVI.m DRES syndrome - DRESS-like reaction - Drug hypersensitivity syndrome
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.a Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.f Tachycardia
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.g QTc prolongation
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.l Cardiac- cardiorespiratory/pulmonary arrest
II. Myocardial dysfunction - Heart failure
II.a Left ventricular dysfunction/failure
II. Myocardial dysfunction - Heart failure
II.c Heart failure (biventricular, congestive)
II. Myocardial dysfunction - Heart failure
II.d Cardiovascular collapse - Cardiogenic shock - Hypotension
II. Myocardial dysfunction - Heart failure
II.e Acute respiratory or cardiopulmonary failure
III. Myocardial ischemia - Coronary artery disease
III.c Coronary vasospasm - Vasospastic angina
III. Myocardial ischemia - Coronary artery disease
III.g ST segment changes
VI. Cardiomyopathy
VI.a Cardiomyopathy (acute, subacute, chronic)
VII. Cardiotoxicity
VII.a ‘Cardiotoxicity’
X. Pulmonary edema
X.b Pulmonary edema, noncardiogenic (NCPE)
X. Pulmonary edema
X.c Interstitial pulmonary edema
XII. Pericardial involvement
XII.b Pericardial effusion (w/wo tamponade)
XIII. Thrombosis - Embolism
XIII.a Pulmonary embolism - Venous thrombosis/thrombo-embolism
XIV. Pleural involvement
XIV.a Pleural effusion (uni or bilateral) (can accompany ILD induced by the drug)
XVI. Hemorrhage - Bleeding - Hematoma(s)
XVI.i Hemoptysis
XXII. Acute respiratory/cardiorespiratory failure
XXII.b Acute lung injury - ARDS
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.k Pulmonary infiltrates
XXXVI. Autoimmune syndromes - Systemic reactions or conditions
XXXVI.y Cytokine release syndrome
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.f Tachycardia
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.j Asystole
VI. Cardiomyopathy
VI.a Cardiomyopathy (acute, subacute, chronic)
XXXVIII. Miscellaneous - Varia
XXXVIII.d Death following exposure or poisoning
XXXVIII. Miscellaneous - Varia
XXXVIII.q Myopathy-Myositis-Polymyositis
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.a Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.e Bradycardia
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.f Tachycardia
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.j Asystole
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.l Cardiac- cardiorespiratory/pulmonary arrest
II. Myocardial dysfunction - Heart failure
II.d Cardiovascular collapse - Cardiogenic shock - Hypotension
IV. Heart block (bundle branch-, AV-block)
IV.a Heart block (bundle branch- or AV-)
V. Myocarditis
V.a Myocarditis (can be fulminate/fulminant)
V. Myocarditis
V.b Eosinophilic myocarditis
VI. Cardiomyopathy
VI.a Cardiomyopathy (acute, subacute, chronic)
VII. Cardiotoxicity
VII.a ‘Cardiotoxicity’
VII. Cardiotoxicity
VII.b Veterinary: Cardiotoxicity
XIV. Pleural involvement
XIV.a Pleural effusion (uni or bilateral) (can accompany ILD induced by the drug)
XVI. Hemorrhage - Bleeding - Hematoma(s)
XVI.e Alveolar hemorrhage (AH), diffuse AH (DAH)
XXII. Acute respiratory/cardiorespiratory failure
XXII.b Acute lung injury - ARDS